Product Launches

What is a product launch as a catalyst?

A product launch is a discrete, time-bound event that fundamentally changes the market's expectations of a company's future revenue and profits. Unlike organic growth, which creeps in quarter after quarter, a launch is a binary event: the product either succeeds or fails, the market either reacts positively or negatively, and the price often adjusts within days. This makes launches the purest form of investment catalyst. AstraZeneca's Covid-19 vaccine (Vaxzevria) was approved in the EU in January 2021 — the stock rose 8% in a week and the company raised its 2021 guidance from $26M to $36M in revenue. In a single press conference, the company's 12-month forecast changed by 40%. That is the power of a successful launch. But catalysts are double-edged: Sinch's launch of MessageMedia in Europe in 2021 was met by cooling sentiment — the stock fell 12% in the month and began the downward spiral that would cost 95% of its value over 18 months. As an analyst you must understand that launches are event-driven, not trend-driven, and that they require a completely different analytical framework than organic growth.

📖 DEFINITION

A catalyst = an identifiable, time-bound event that is expected to move the market's appraisal of a company's value. Product launches are the most common catalyst. Other examples: quarterly reports, FDA approvals, M&A news, regulatory decisions.

Why catalysts are fundamentally different

Growth investors buy companies because they are expected to grow 20% per year for several years. Catalyst investors buy companies because a specific event within 6-12 months is expected to move the price 30-50%. These are two fundamentally different strategies. Growth requires patience and right business-quality; a catalyst requires right timing and right event-quality. A catalyst investor can buy a company with mediocre growth if a major launch is waiting — and sell the day after the launch, regardless of outcome. This is called 'event-driven investing' and is the hedge fund strategy behind many actually measurable gains. Joel Greenblatt's special-situation strategy (described in 'You Can Be a Stock Market Genius') is built on exactly this: identify catalysts, calculate probability-weighted return, and invest where the expected value is strongly positive. For the Swedish market, product launches are the most common and most accessible catalyst — especially in pharmaceuticals (AstraZeneca, Getinge, Karo Pharma), tech (Spotify, Sinch, Evolution Gaming), and industry (SAAB Gripen E, Volvo CE electrification, Ericsson 5G).

💡 INSIGHT

The difference between growth investing and catalyst investing: growth buys the 'right company', a catalyst buys the 'right event'. You can be right about the company and wrong about the catalyst — and vice versa. Those who understand both strategies have two tools, not one.

The catalyst's three time phases

A product launch has three clear time phases, each with its own price dynamics. Phase 1 — Anticipation: 3-12 months before the launch, the market begins pricing in the probability of success. The stock rises gradually, often 20-40% before the launch itself. AstraZeneca's stock rose from 80 SEK in March 2020 to 110 SEK in December 2020 — a 38% rise — on vaccine approval expectations alone. This is the 'buy the rumor' phase. Phase 2 — Event (the launch itself): on launch day and the days immediately after, the price reacts sharply. If the launch exceeds expectations, the stock can rise a further 10-20%. If it fails, it falls 15-30%. If it matches expectations, it often falls 3-8% — this is the 'sell the news' effect. Phase 3 — Verification: 1-6 months after the launch, the market tests whether the initial reaction was correct. Has the product gained traction? Does the sales live up to the hype? Here the price can reverse in both directions. Spotify's US launch in April 2018: the stock rose 12% on day 1, fell 8% in the first month, and then rose 60% over 6 months as user growth verified the success. Understanding which phase you are in is half the catalyst strategy.

⚡ KEY INSIGHTS Product launches are binary events — they either succeed or fail at a predetermined time Catalyst investing differs from growth investing: right event vs right company Three time phases: Anticipation (3-12 months before), Event (launch day), Verification (1-6 months after) Buy-the-rumor-sell-the-news is most common; exceptions require the launch to exceed expectations by a wide margin 2

Pipeline strength as a valuation factor

A company's pipeline is the sum of all products under development that do not yet generate revenue. For pharmaceutical companies this is the dominant valuation factor — AstraZeneca has over 170 projects in the pipeline, of which 50+ in late clinical phase (Phase II-III). Each project has a probability of approval (typically 10-60% depending on phase) and a potential market (typically $100M-$5B per approved product). The sum of (probability × market × margin × duration) gives the pipeline's risk-adjusted net present value (rNPV). For a mature pharmaceutical company, rNPV can constitute 30-50% of the company's total value. AstraZeneca 2020: the company was valued at £100M but their Covid vaccine pipeline had an rNPV of £10-15M at a 60% probability of approval. When the vaccine was approved and the probability went to 100%, the value increased by £20-25M — the stock rose 25% over six months. As an analyst you MUST understand the rNPV method if you want to value catalyst-driven companies. Without it, you become either a 'katta' investor who buys on hype or a cynic who never pays for the pipeline's potential.

📖 DEFINITION

rNPV (risk-adjusted Net Present Value) = the sum of each pipeline project's (probability of approval × expected annual revenue × gross margin × duration × discount factor). Industry standard for pharmaceutical valuation.

The S-curve and adoption speed

A successful product launch follows an S-curve: slow start (early adopters), acceleration (mass market), maturity (late adopters), and deceleration (saturation). Identifying where on the S-curve a newly launched product sits is critical. Early S-curve (penetration < 10% of addressable market) means success is only beginning — this is where you buy if you believe in the product. Mid S-curve (10-50% penetration) is the fastest value creation phase — the company's growth accelerates. Late S-curve (>50%) means deceleration is near. Spotify after the 2018 US launch was in the early S-curve (penetration ~5% of addressable market) — buyers in 2018 got the entire mass-market acceleration up to 2022. Evolution Gaming 2018-2020 was in the mid S-curve — the stock rose 5x in 2 years. Today (2024) Evolution is in the late S-curve for live casino (penetration > 50%) and growth has decelerated noticeably — the multiple has contracted from P/E 50 to P/E 15. The question to ask: 'Is this launch at the beginning, middle, or end of its S-curve?' The answer determines whether you should buy, hold, or avoid.

✓ TIP

Calculate penetration = (current sales or users) / (addressable market). <10% = early (buy signal). 10-50% = middle (hold). >50% = late (caution). For SaaS: TAM × take rate. For pharmaceuticals: patient population × price × treatment duration.

Competing launches and timing

⚡ KEY INSIGHTS Pipeline = the sum of all development products; rNPV = risk-adjusted value of the pipeline The S-curve determines whether the launch is in early (<10%), middle (10-50%), or late (>50%) phase Competing launches destroy premium pricing; 'first-in-class' gives 6-12 months monopoly Always map 3-5 competitor pipelines and their timeline before you invest 3